ARMP Quote, Financials, Valuation and Earnings

Perspective Therapeutics has a net margin of -- compared to Armata Pharmaceuticals's net margin of --. Armata Pharmaceuticals's return on equity of -- beat Perspective Therapeutics's return on equity of --.

Armata Pharmaceuticals has a consensus price target of $7.00, signalling upside risk potential of 243.12%. On the other hand Perspective Therapeutics has an analysts' consensus of $16.15 which suggests that it could grow by 396.92%. Given that Perspective Therapeutics has higher upside potential than Armata Pharmaceuticals, analysts believe Perspective Therapeutics is more attractive than Armata Pharmaceuticals.

Armata Pharmaceuticals has a beta of 0.777, which suggesting that the stock is 22.301% less volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.129, suggesting its more volatile than the S&P 500 by 12.894%.

Armata Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Armata Pharmaceuticals pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

Armata Pharmaceuticals quarterly revenues are --, which are smaller than Perspective Therapeutics quarterly revenues of --. Armata Pharmaceuticals's net income of -$5.5M is higher than Perspective Therapeutics's net income of -$15.1M. Notably, Armata Pharmaceuticals's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Armata Pharmaceuticals is 739.11x versus 17.55x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Electromed has a net margin of -- compared to Armata Pharmaceuticals's net margin of 10.05%. Armata Pharmaceuticals's return on equity of -- beat Electromed's return on equity of 15.62%.

Armata Pharmaceuticals has a consensus price target of $7.00, signalling upside risk potential of 243.12%. On the other hand Electromed has an analysts' consensus of -- which suggests that it could grow by 11.56%. Given that Armata Pharmaceuticals has higher upside potential than Electromed, analysts believe Armata Pharmaceuticals is more attractive than Electromed.

Armata Pharmaceuticals has a beta of 0.777, which suggesting that the stock is 22.301% less volatile than S&P 500. In comparison Electromed has a beta of 0.285, suggesting its less volatile than the S&P 500 by 71.506%.

Armata Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Armata Pharmaceuticals pays -- of its earnings as a dividend. Electromed pays out -- of its earnings as a dividend.

Armata Pharmaceuticals quarterly revenues are --, which are smaller than Electromed quarterly revenues of $14.7M. Armata Pharmaceuticals's net income of -$5.5M is lower than Electromed's net income of $1.5M. Notably, Armata Pharmaceuticals's price-to-earnings ratio is -- while Electromed's PE ratio is 41.08x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Armata Pharmaceuticals is 739.11x versus 4.62x for Electromed. Usually stocks with elevated PS ratios are considered overvalued.

Protalix BioTherapeutics has a net margin of -- compared to Armata Pharmaceuticals's net margin of 18.02%. Armata Pharmaceuticals's return on equity of -- beat Protalix BioTherapeutics's return on equity of -29.54%.

Armata Pharmaceuticals has a consensus price target of $7.00, signalling upside risk potential of 243.12%. On the other hand Protalix BioTherapeutics has an analysts' consensus of -- which suggests that it could grow by 686.52%. Given that Protalix BioTherapeutics has higher upside potential than Armata Pharmaceuticals, analysts believe Protalix BioTherapeutics is more attractive than Armata Pharmaceuticals.

Armata Pharmaceuticals has a beta of 0.777, which suggesting that the stock is 22.301% less volatile than S&P 500. In comparison Protalix BioTherapeutics has a beta of 0.741, suggesting its less volatile than the S&P 500 by 25.895%.

Armata Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix BioTherapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Armata Pharmaceuticals pays -- of its earnings as a dividend. Protalix BioTherapeutics pays out -- of its earnings as a dividend.

Armata Pharmaceuticals quarterly revenues are --, which are smaller than Protalix BioTherapeutics quarterly revenues of $18M. Armata Pharmaceuticals's net income of -$5.5M is lower than Protalix BioTherapeutics's net income of $3.2M. Notably, Armata Pharmaceuticals's price-to-earnings ratio is -- while Protalix BioTherapeutics's PE ratio is 115.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Armata Pharmaceuticals is 739.11x versus 3.06x for Protalix BioTherapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of -- compared to Armata Pharmaceuticals's net margin of -17.98%. Armata Pharmaceuticals's return on equity of -- beat Xtant Medical Holdings's return on equity of -35.98%.

Armata Pharmaceuticals has a consensus price target of $7.00, signalling upside risk potential of 243.12%. On the other hand Xtant Medical Holdings has an analysts' consensus of -- which suggests that it could grow by 469.04%. Given that Xtant Medical Holdings has higher upside potential than Armata Pharmaceuticals, analysts believe Xtant Medical Holdings is more attractive than Armata Pharmaceuticals.

Armata Pharmaceuticals has a beta of 0.777, which suggesting that the stock is 22.301% less volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of 0.357, suggesting its less volatile than the S&P 500 by 64.342%.

Armata Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Armata Pharmaceuticals pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

Armata Pharmaceuticals quarterly revenues are --, which are smaller than Xtant Medical Holdings quarterly revenues of $27.9M. Armata Pharmaceuticals's net income of -$5.5M is lower than Xtant Medical Holdings's net income of -$5M. Notably, Armata Pharmaceuticals's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Armata Pharmaceuticals is 739.11x versus 0.46x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.